Optimizing Epcoritamab Dosing and Treatment Considerations in Second-Line Follicular Lymphoma

EP: 1.Introduction and Exploring the Financial Burden of Follicular Lymphoma

EP: 2.Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma

EP: 3.Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy

EP: 4.Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma

EP: 5.Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma

EP: 6.Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma

EP: 7.Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma

EP: 8.Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma

EP: 9.Operational Challenges and Solutions for Implementing Bispecific Antibodies in Follicular Lymphoma

EP: 10.Best Practices for Operationalizing Bispecific Antibody Therapy in Follicular Lymphoma

Now Viewing

EP: 11.Optimizing Epcoritamab Dosing and Treatment Considerations in Second-Line Follicular Lymphoma

In the second-line setting for follicular lymphoma, selecting the appropriate epcoritamab dosing schedule is crucial to balance efficacy, safety, and patient convenience. The newly approved second-line regimen often mirrors the structure used in prior indications but may include modifications in dose frequency or duration to optimize response in combination with other therapies, such as rituximab and lenalidomide. Key treatment considerations include monitoring for cytokine release syndrome, immune-mediated adverse events, and cytopenias, with proactive management strategies to minimize toxicity. Patient factors—such as comorbidities, prior therapy, and logistical feasibility of frequent clinic visits—also influence dosing decisions. Understanding the differences between the original and updated indications ensures clinicians can safely integrate epcoritamab into second-line practice while maintaining consistent disease control and preserving quality of life. This approach supports personalized therapy planning and improved patient outcomes.